Monalizumab
(Redirected from IPH2201)
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | NKG2A |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]
Mechanism of action
[edit | edit source]Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5][6]
References
[edit | edit source]- ^ A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
- ^ IPH2201 studies
- ^ First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
- ^ AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
